-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Jason Corum
Increasing Partnering at BIO
Mike May from Biotech Tallies writes: At the 2011 BIO International Convention, the number of one-on-one partnering meetings soared to 21,183… The increasing number of such meetings probably reflects the growth in biotechnology, the escalating importance of BIO’s annual meeting and the expanding need to partner for success in this field.
Stopping ALS: An interview with Dr. Perrin from ALS TDI
What is ALS? How widespread is the disease? Are there any treatments for ALS? Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease and outside the US as Motor Neuron Disease (MND) or Charcot’s Disease, is a progressive neurodegenerative disease that attacks motor neurons in the brain (upper motor neurons) and spinal cord (lower motor neurons) and affects muscle function. Dr. Steven Perrin is the CEO, CSO and Vice Chairman of the ALS Therapy Read More >
Could 3 minutes reshape California’s biotech future?
Ron Leuty from BiotechSF writes: In just three minutes the other day, Maryland received more than 180 applications for its $8 million biotech tax credit program. The program, which rewards investors for putting cash in biotech startups, is one of many that states are offering to jumpstart or grow their life sciences communities.
They engineered a better salmon, so why is Congress blocking it?
Steven Salzberg from Fighting Pseudoscience writes: What happened to genetically modified salmon? A few months back I was looking forward to my first taste of the new AquaBounty salmon, which grows to maturity twice as fast as wild salmon. Will it taste just as good? Better? I thought I’d know soon. But then politics intervened. Fighting Pseudoscience is a blog from Forbes.
#Bio2011: After the Party is Over
Shane Climie, Ph.D., from HealthWorks Collective writes: For the thousands of life science industry representatives who attend the Biotechnology Industry Organization Annual Convention each year, the last few days have been similar to a favorite holiday: exciting, long-awaited, and too quickly over. We’re glad you enjoyed the 2011 BIO International Convention!




